Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolism and PK of BI 1358894 in Healthy Male Volunteers
NCT04567316Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bi 1358894 in major depressive disorder (MDD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Mass Balance and Recoveries of [14C] BI 1358894 Total Radioactivity in Urine and Faeces up to 50 days. Started Oct 2020; status: completed.
02
Drugs
bi 1358894
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04567316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04567316.